Actions matter: giving Ph+ CML patients the best chance of optimal outcomes

Not taking action at key milestones is a missed opportunity to optimize patient management and reduce the risk of potential progression and death

Optimal responses to first-line therapy as defined by the ELN1

NOT TAKING ACTION at key milestones is a MISSED OPPORTUNITY to reduce risk of potential progression and death

ELN Recommends Testing Every 3 Months until MMR Is Achieved1

  • Patients tested fewer than 3 to 4 times per year may experience increased risk of progression or death, increased inpatient admissions and medical service costs, and reduced adherence5-7

Monitor and address suboptimal responses

a EFS was defined as the time from start of treatment until any of the following events occurring during study treatment: loss of CHR, loss of MCyR, progression to AP/BC, or death due to any cause.

AP, advanced phase; BC, blast crisis; CHR, complete hematologic response; CML, chronic myeloid leukemia; EFS, event-free survival; ELN, European LeukemiaNet; EMR, early molecular response; IS, International Scale; MCyR, major cytogenetic response; MMR, major molecular response; MR4, BCR-ABLIS ≤ 0.01%; MR4.5, BCR-ABLIS ≤ 0.0032%; OS, overall survival; Ph+, Philadelphia chromosome-positive; TKI, tyrosine kinase inhibitor.

  1. Baccarani M, et al. Blood. 2013;122:872-884.
  2. Marin D, et al. J Clin Oncol. 2012;30:232-238.
  3. Hanfstein B, et al. Leukemia. 2012;26:2096-2102.
  4. Hughes TP, et al. Blood. 2010;116:3758-3765.
  5. Goldberg S, et al. Curr Med Res Opin. 2013;29:1075-1082.
  6. Guerin A, et al. Curr Med Res Opin. 2014;30(7):1345-1352.
  7. Guerin A, et al. J Med Econ. 2014;17:89-98.